Next-Generation Drug Conjugates Market
完整報告名稱與涵蓋範圍
Next-Generation Drug Conjugates Market Size, Share & Trends Analysis Report, By Conjugate Type (Bispecific and Biparatopic ADCs, Dual-Payload ADCs, Peptide-Drug Conjugates, Immune-Stimulating Antibody Conjugates, Degrader-Antibody and Other Novel Conjugates), By Indication (Breast Cancer, Lung Cancer, Gastrointestinal Cancers, Hematologic Malignancies, Other Solid Tumors), By Development Stage (Preclinical and Phase 1, Phase 2 and Phase 3, Approved and Commercial), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The next-generation drug conjugates market covers targeted conjugate therapeutics that move beyond the classical monospecific antibody-cytotoxic ADC design, including bispecific and biparatopic ADCs, dual-payload ADCs, peptide-drug conjugates, immune-stimulating antibody conjugates and degrader-antibody conjugates. Conventional ADCs are covered in a separate InsightAce study, and radioligand conjugates are addressed in the radiopharmaceutical series; both are excluded here to keep the revenue boundary clean.
Innovation is driven by the limitations of first-generation designs: on-target toxicity, resistance through antigen loss and narrow therapeutic windows. Bispecific formats improve internalisation and tumor selectivity, dual payloads counter heterogeneity, peptide carriers reach targets antibodies cannot, and immune-stimulating payloads convert a cytotoxic modality into an immunotherapy. Large pharmaceutical companies have secured many of these platforms through licensing deals, especially with Chinese biotechnology companies, and several programs are in late-stage trials. Commercial revenue in the forecast window depends on approval timing, which the study models explicitly rather than assuming.
The United States, Japan, Europe and China host the leading developers, with China now originating a large share of the global conjugate pipeline. Competition combines ADC incumbents, platform biotechnology companies and licensing-driven pharmaceutical groups.
The InsightAce study includes revenue forecasts in US$ for all conjugate type, indication, development stage and end user and regional segments across 2026-2035, segment-level trend analysis, competitive positioning assessment and company profiles.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Next-Generation Drug Conjugates Market Snapshot
Chapter 4. Global Next-Generation Drug Conjugates Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Conjugate Type Estimates & Trend Analysis
5.1. Conjugate Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Conjugate Type:
5.2.1. Bispecific and Biparatopic ADCs
5.2.2. Dual-Payload ADCs
5.2.3. Peptide-Drug Conjugates
5.2.4. Immune-Stimulating Antibody Conjugates
5.2.5. Degrader-Antibody and Other Novel Conjugates
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Breast Cancer
6.2.2. Lung Cancer
6.2.3. Gastrointestinal Cancers
6.2.4. Hematologic Malignancies
6.2.5. Other Solid Tumors
Chapter 7. Market Segmentation 3: By Development Stage Estimates & Trend Analysis
7.1. Development Stage & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Development Stage:
7.2.1. Preclinical and Phase 1
7.2.2. Phase 2 and Phase 3
7.2.3. Approved and Commercial
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Hospitals and Cancer Centers
8.2.2. Specialty Pharmacies
Chapter 9. Next-Generation Drug Conjugates Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Daiichi Sankyo Company, Limited
11.2. AstraZeneca plc
11.3. Merck & Co., Inc.
11.4. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
11.5. GSK plc
11.6. Hansoh Pharmaceutical Group Company Limited
11.7. AbbVie Inc.
11.8. Pfizer Inc.
11.9. BioNTech SE
11.10. Duality Biologics (Suzhou) Co., Ltd.
11.11. Sutro Biopharma, Inc.
11.12. Mersana Therapeutics, Inc.
11.13. Bicycle Therapeutics plc
11.14. Zymeworks Inc.
11.15. Orum Therapeutics Inc.
圖表清單 List of Tables & Figures
Table 1. Global Next-Generation Drug Conjugates Market Revenue Forecast by Conjugate Type, 2026-2035 (US$ Mn)
Figure 1. Global Next-Generation Drug Conjugates Market Segmentation Overview
Table 2. Global Next-Generation Drug Conjugates Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Next-Generation Drug Conjugates Market Share by Conjugate Type, 2026 & 2035
Table 3. Global Next-Generation Drug Conjugates Market Revenue Forecast by Development Stage, 2026-2035 (US$ Mn)
Figure 3. Next-Generation Conjugate Pipeline by Format, Phase and Originating Region
Table 4. Global Next-Generation Drug Conjugates Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Global Next-Generation Drug Conjugates Market Share by Indication, 2026 & 2035
Table 5. North America Next-Generation Drug Conjugates Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Licensing Deal Flow for Novel Conjugate Platforms, 2023-2026
Table 6. Europe Next-Generation Drug Conjugates Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Next-Generation Drug Conjugates Growth Opportunity Analysis
Table 7. Asia Pacific Next-Generation Drug Conjugates Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Design Attributes Addressing Resistance and Toxicity Limitations of First-Generation ADCs
Table 8. Latin America Next-Generation Drug Conjugates Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Next-Generation Drug Conjugates Market Participants
Table 9. Middle East & Africa Next-Generation Drug Conjugates Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們